In the present study, compared with helical I-125 seed implant with TACE and sorafenib, the utilization of helical I-125 seed implant in conjunction with TACE, lenvatinib, and PD-1 inhibitors for HCC with MPVTT extend median OS to 16.1 months, mirroring the OS of 17.7 months by Zhang et al. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.